SCHEMBL2276151

SCHEMBL2276151

CN(C)CCNC(=O)Cc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
KMT2A Q03164 3/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
LMNA P02545 2/20 0.56
POLB P06746 1/20 0.55
CNR2 P34972 2/20 0.55
CNR1 P21554 1/20 0.55
GAA P10253 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14679387 0.85 HPGD (0.64) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL849368 0.84 L3MBTL1 (0.63) ALDH1A1KMT2AMEN1LMNACNR2
SCHEMBL5582645 0.84 HDAC1 (0.49) ALDH1A1LMNACNR2CYP1A2CYP2D6
SCHEMBL8139484 0.84 HDAC1 (0.49) CYP1A2CYP2D6HPGDCYP2C19L3MBTL1
SCHEMBL11570271 0.83 KCNH2 (0.69) ALDH1A1KMT2AMEN1LMNACNR1
Hydrochloric Acid SCHEMBL11570396 0.82 KCNH2 (0.67) ALDH1A1KMT2AMEN1CNR2CNR1
SCHEMBL13481192 0.81 ALDH1A1 (0.61) ALDH1A1KMT2AMEN1NPC1RAB9A
SCHEMBL3109264 0.81 KCNH2 (0.49) ALDH1A1GAASMN1; SMN2CYP1A2CYP2D6
SCHEMBL8117324 0.80 RORC (0.48) POLBCYP1A2CYP2D6HPGDCYP2C19
SCHEMBL5681870 0.80 CA12 (0.75) ALDH1A1KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994172-B2 [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism EXELIXIS, INC. (US) 2011-08-09 US disclosed
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases EXELIXIS, INC. (US) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases PDPK1, MTOR, RPS6KA2 ALDH1A1 4083/4885KMT2A 3363/4885MEN1 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.